Community-dwelling obese participants with a body mass index (BMI) =30 kg/m2 to =40 kg/m2 Nutritional, Metabolic, Endocrine Obesity
Conditions
Interventions
Randomized, double-blind, cross-over, single centre clinical supplementation trial, in which 24 subjects (12 men and 15 women) will be randomised to one of two orders of administration of:
Sponsors
Spanish Ministry of Economy and Competitiveness (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Obese patients 2. Body mass index (BMI) = 30 kg/m2 to =40 kg/m2 3. Aged 20 - 60 years, either sex
Exclusion criteria
Exclusion criteria: 1. Intake of antioxidant supplement or acetylsalicylic acid or any other drug with established antioxidative properties 2. Athletes with physical activity (PA >3000 kcal/day in leisure-time 3. BMI 40 kg/m2) 4. Diabetes, multiple allergies, intestinal diseases 5. Any condition that limits the mobility of the subject making study visits impossible 6. Life threatening illness such as cancer or severe disease with a lowered expected 3 year survival 7. Any other disease or condition that would worsen the adherence to the measurements or treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Inflammatory parameters measured at baseline and before and after each intervention: 1.1. Serum inmunoglobulines A, G, and M 1.2. Complement 3(C3) and 4 (C4) 1.3. Plasma interleukine-8 (IL8), monocyte chemotactic protein-1(MCP-1), and vascular endothelial growth factor (VEGF) . | — |
Secondary
| Measure | Time frame |
|---|---|
| Oxidative damage: Plasma lipids and lípid peroxides will be determined at baseline and 3 weeks after each intervention period. | — |
Countries
Spain
Outcome results
None listed